Trial Profile
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; BI 1206 (Primary) ; BI 1206 (Primary) ; Rituximab
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors BioInvent International
- 09 Feb 2024 According to a BioInvent International media release, company announced clinical supply agreement with AstraZeneca to support this study.Under the terms of the supply agreement, AstraZeneca will provide Calquenc for use in combination with BI-1206 and rituximab. This trial will be expanded to include the triplet arm.
- 09 Feb 2024 Drug Calquence (acalabrutinib) has been added to study protocol for the treatment of patients with follicular lymphoma who have progressed or are refractory to rituximab, according to a BioInvent International media release.
- 09 Feb 2024 According to a BioInvent International media release, the calquence expansion cohort is expected to enroll approximately 30 patients at sites in Sweden, Spain, the US, and Brazil.